

# Issue Brief

FEDERAL ISSUE BRIEF



Analysis provided for MHA by Larry Goldberg, Goldberg Consulting

January 17, 2025

## CMS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations

The Centers for Medicare & Medicaid Services (CMS) today announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations. In accordance with the **Inflation Reduction Act**, the negotiations with participating drug companies for these 15 drugs will occur in 2025 and any negotiated prices will become effective in 2027.

The selected drugs accounted for about \$41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14 percent. When combined with the total gross covered prescription drug costs under Medicare Part D of the 10 drugs selected for the first cycle of negotiations over that same time period, this represents over a third of total gross covered prescription drug costs under Medicare Part D.

The following chart identifies the 15 drugs.

Drug Name	Commonly Treated Conditions*	Total Part D Gross Covered Prescription Drug Costs from November 2023-October 2024	Number of Medicare Part D Enrollees Who Used the Drug from November 2023-October 2024
Ozempic; Rybelsus; Wegovy	Type 2 diabetes; Type 2 diabetes and cardiovascular disease; Obesity/overweight and cardiovascular disease	\$14,426,566,000	2,287,000
Trelegy Ellipta	Asthma; Chronic obstructive pulmonary disease	\$5,138,107,000	1,252,000
Xtandi	Prostate cancer	\$3,159,055,000	35,000
Pomalyst	Kaposi sarcoma; Multiple myeloma	\$2,069,147,000	14,000
Ibrance	Breast cancer	\$1,984,624,000	16,000
Ofev	Idiopathic pulmonary fibrosis	\$1,961,060,000	24,000
Linzess	Chronic idiopathic constipation; Irritable bowel syndrome with constipation	\$1,937,912,000	627,000
Calquence	Chronic lymphocytic leukemia/small lymphocytic lymphoma; Mantle cell lymphoma	\$1,614,250,000	15,000

Questions? Contact Andrew Wheeler, MHA's Vice President of Federal Finance, at 573-893-3700 | ext. 1336 or [awheeler@mhanet.com](mailto:awheeler@mhanet.com).

4712 Country Club Drive, Jefferson City, Mo. 65109  
P.O. Box 60, Jefferson City, Mo. 65102  
573/893-3700 | [www.mhanet.com](http://www.mhanet.com)



Drug Name	Commonly Treated Conditions*	Total Part D Gross Covered Prescription Drug Costs from November 2023-October 2024	Number of Medicare Part D Enrollees Who Used the Drug from November 2023-October 2024
Austedo; Austedo XR	Chorea in Huntington's disease; Tardive dyskinesia	\$1,531,855,000	26,000
Breo Ellipta	Asthma; Chronic obstructive pulmonary disease	\$1,420,971,000	634,000
Tradjenta	Type 2 diabetes	\$1,148,977,000	278,000
Xifaxan	Hepatic encephalopathy; Irritable bowel syndrome with diarrhea	\$1,128,314,000	104,000
Vraylar	Bipolar I disorder; Major depressive disorder; Schizophrenia	\$1,085,788,000	116,000
Janumet; Janumet XR	Type 2 diabetes	\$1,082,464,000	243,000
Otezla	Oral ulcers in Behçet's Disease; Plaque psoriasis; Psoriatic arthritis	\$994,001,000	31,000

Questions? Contact Andrew Wheeler, MHA's Vice President of Federal Finance, at 573-893-3700 | ext. 1336 or [awheeler@mhanet.com](mailto:awheeler@mhanet.com).

4712 Country Club Drive, Jefferson City, Mo. 65109  
P.O. Box 60, Jefferson City, Mo. 65102  
573/893-3700 | [www.mhanet.com](http://www.mhanet.com)

